Keywords: agouron, tests, ag3340, phase, ii, trials, pharmaceuticals
Agouron Tests AG3340 In Phase II Trials
Article | 21 September 1998
Agouron Pharmaceuticals has initiated Phase II safety and efficacyclinical trials of AG3340 in patients with age-related macular degeneration. The anti-angiogenesis ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
